By Woody Sherman, CSO and Vipin Sachdeva, Principal Investigator, Silicon Therapeutics
[Editor’s note: Today we hear from Boston, MA-based Silicon Therapeutics, which is marshalling all the resources it can muster to find new medicines for important diseases.]
As an integrated computational drug discovery firm, we recently deployed our INSITE Screening platform on Google Cloud Platform (GCP) to analyze over 10 million commercially available molecular compounds as potential starting materials for next-generation medicines. In one week, we performed over 500 million docking computations to evaluate how a protein responds to a given molecule. Each computation involved a docking program that predicted the preferred orientation of a small molecule to a protein and the associated energetics so we could assess whether or not it will bind and alter the function of the target protein.
With a combination of Google Compute Engine standard and Preemptible VMs, we used up to 16,000 cores, for a total of 3 million core-hours and a cost of about $30,000. While this might sound like a lot of time and money, it’s a lot less expensive and a lot faster than experimentally screening all compounds. Using a physics-based approach such as our INSITE platform is much more computationally expensive than some other computational screening approaches, but it allows us to find novel binders without the use of any prior information about active compounds (this particular target has no drug-like compounds known to bind). In a final stage of the calculations we performed all-atom molecular dynamics (MD) simulations on the top 1,000 molecules to determine which ones to purchase and experimentally assay for activity.
The bottom line: We successfully completed the screen using our INSITE platform on GCP and found several molecules that have recently been experimentally verified to have on-target and cell-based activity.
We chose to run this high-performance computing (HPC) job on GCP over other public cloud providers for a number of reasons:
We initialized multiple clusters for the screening; specifically, our cluster’s front-end consisted of three full-priced n1-highmem-32 VM instances with 208GB of RAM that ran the queuing system, and that connected to a 2TB SSD NFS filestore that housed the compound library. Each of these front-end nodes then spawned up to 128 compute nodes configured as n1-highcpu-32 Preemptible VMs, each with 28.8GB of memory. Those compute nodes performed the actual molecular compound screens, and wrote their results back to the filestore. Preemptible VMs run for a maximum of 24 hours; when that time elapsed, the front-end nodes drained any jobs remaining on the compute nodes and re-spawned a new set of nodes until all 10 million compounds had been successfully run.
To manage compute jobs, we enlisted the help of two popular open-source tools: Slurm, a workload manager used by 60% of the world’s TOP500 clusters, and ElastiCluster, which provides a command-line tool to create, manage and setup compute clusters hosted on a variety of cloud infrastructures. Using these open-source packages is economical, provides the lion’s share of the functionality of paid software solutions and ensures we can run our workloads in-house or elsewhere.
But ultimately, the biggest benefit of using GCP was being able to more thoroughly screen compounds than we could have done with in-house resources. The target protein in this particular study was highly flexible, and having access to massive amounts of compute power allowed us to more accurately model the underlying physics of the system by accounting for protein flexibility. This yielded more active compounds than we would have found without the GCP resources.
The reality is that all proteins are flexible, and undergo some form of induced fit upon ligand binding, so treating protein flexibility is always important in virtual screening if you want the best results. Most molecular docking programs only account for ligand flexibility, so if the receptor structure is not quite right then active compounds might not fit and therefore be missed, no matter how good the docking program is. Our INSITE screening platform incorporates protein flexibility in a novel way that can greatly improve the hit rate in virtual screening, even as it requires a lot of computational resources when screening millions of commercially available compounds.
|Example of the dynamic nature of protein target (Interleukin018, IL18)|
From the initial 10 million compounds, we prioritized 250 promising compounds for experimental validation in our lab. As a small company, we don’t have the capabilities to experimentally screen millions of compounds, and there’s no need to do so with an accurate virtual screening approach like we have in our INSITE platform. We’re excited to report that at least five of these compounds have shown activity in human cells, suggesting them as promising starting points for new medicines. To our knowledge, there are no drug-like small molecule activators of this important and challenging immune-oncology target.
To learn more about the science at Silicon Therapeutics, please visit our website. And if you’re an engineer with expertise in high performance computing, GPUs and/or molecular simulations, be sure to visit our job listings.